stockrow
Saturday 7 November 2026
Export BMGL’s income statement to Excel — free account
Basel Medical Group Ltd
BMGL Healthcare Medical Care Facilities
Basel Medical Group Ltd’s revenue for fiscal 2026 (year ended June 2026) was $12.8 million, up 43.9% from fiscal 2025.
5.25
0.06
+1.16%
Follow BMGL
Alert me
| Jun '26 | Jun '25 | Jun '24 | |
|---|---|---|---|
Piotroski F-Score |
4 | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.34) | 8.19 | — |
P/Operating CF |
0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.06) | 0.00 | 0.00 |
EV/FCF |
(1.03) | 0.00 | 0.00 |
Quick Ratio |
1.20 | 1.19 | 2.03 |
Current Ratio |
1.23 | 1.23 | 2.26 |
Net Debt/EBITDA |
(18.33) | (0.42) | 0.90 |
Debt/Assets |
48.67% | 20.29% | 26.30% |
Debt/Equity |
1.91 | 0.70 | 0.57 |
Asset Turnover |
0.95 | 0.70 | 0.00 |
Operating CF/Net income |
0.91 | 0.36 | 1.21 |
Capex/Depreciation |
(0.70) | (0.51) | (0.26) |
Interest Coverage |
(1.72) | (5.67) | 14.65 |
| (15.90%) | (202.11%) | 0.00% | |
| (4.32%) | (75.17%) | 0.00% | |
ROIC |
(3.93%) | (13.62%) | 16.29% |
Return on Tangible Assets |
(29.53%) | (446.95%) | 22.92% |
Average Days of Receivables |
249.63 | 313.78 | 456.20 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
56.18% | 56.52% | 36.21% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.82% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 |
Graham Number |
— | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% |
Revenue per Share |
8.10 | 5.69 | 5.48 |
Operating CF per Share |
(0.34) | (2.18) | 1.37 |
Capex per Share |
(0.12) | (0.03) | 0.00 |
Free Cash Flow per Share |
(0.46) | (2.21) | 1.36 |
Cash per Share |
0.26 | 1.50 | 1.06 |
Shareholders Equity per Share |
2.22 | 2.44 | 4.12 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
2.22 | 2.44 | 4.12 |
Free Cash Flow |
(0.72) | (3.46) | 1.85 |
Working Capital |
1.75 | 1.91 | 6.65 |
Capital Expenditures |
(0.19) | (0.04) | (0.01) |
Net Current Asset Value |
(0.87) | 0.89 | 5.48 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
1.24 | 0.39 | 0.87 |
Cash ROIC |
(6.83%) | (39.06%) | 18.12% |
Accounts Receivable Turnover |
1.56 | 1.05 | 0.00 |
Accounts Payable Turnover |
0.75 | 0.54 | 0.00 |
Inventory Turnover |
12.93 | 11.38 | 0.00 |
Average Days of Payables |
326.91 | 998.82 | 418.22 |
Days of Inventory on Hand |
21.23 | 54.38 | 11.71 |
Average Receivables |
8.21 | 8.46 | — |
Average Payables |
4.09 | 3.67 | — |
Average Inventory |
0.24 | 0.17 | — |
Average Assets |
13.50 | 12.64 | — |
Average Common Equity |
3.67 | 4.70 | — |
Columns are period end dates · fundamentals updated 3 Nov 2026